Detalhe da pesquisa
1.
Publisher Correction: GDF15 mediates the effects of metformin on body weight and energy balance.
Nature;
578(7796): E24, 2020 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32051582
2.
GDF15 mediates the effects of metformin on body weight and energy balance.
Nature;
578(7795): 444-448, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31875646
3.
The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT).
Diabetologia;
67(1): 74-87, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37878066
4.
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
Diabetologia;
67(5): 822-836, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38388753
5.
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
Circulation;
147(13): 1004-1013, 2023 03 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36802715
6.
Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.
Circulation;
147(25): 1872-1886, 2023 06 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37154040
7.
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
Circulation;
148(8): 651-660, 2023 08 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37603600
8.
Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
Circulation;
147(22): 1670-1683, 2023 05 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37039015
9.
Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
Lancet;
401(10391): 1878-1890, 2023 06 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37156255
10.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet;
402(10402): 613-626, 2023 08 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37385275
11.
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
N Engl J Med;
385(10): 896-907, 2021 09 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34215025
12.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
N Engl J Med;
385(16): 1451-1461, 2021 10 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34449189
13.
Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
Am Heart J;
271: 38-47, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38401646
14.
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Am Heart J;
267: 1-11, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37758044
15.
Multiple Cardiac Biomarkers to Improve Prediction of Cardiovascular Events: Findings from the Generation Scotland Scottish Family Health Study.
Clin Chem;
70(2): 403-413, 2024 02 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38069915
16.
Natriuretic Peptides and Prognosis in Patients With Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events.
J Card Fail;
2024 Apr 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38614444
17.
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.
Diabetes Obes Metab;
26(4): 1216-1223, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38116691
18.
Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model.
Diabetes Obes Metab;
26(6): 2229-2238, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38456579
19.
Effectiveness of lifestyle interventions/culturally bespoke programmes in South Asian ethnic groups targeting weight loss for prevention and/or remission of type 2 diabetes: a systematic review and meta-analysis of intervention trials.
J Hum Nutr Diet;
37(2): 550-563, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38234263
20.
Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions.
Curr Cardiol Rep;
26(3): 61-71, 2024 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38551786